Dr. Markus Diefenbacher is a group leader at the Mildred Scheel Early Career Centre for Cancer Research (MSNZ) of the University of Würzburg and the University Hospital Würzburg. He has been nominated as Associated Editor of the Nature Publishing Group’s journal Oncogene with effect from 1 June 2023.
Diefenbacher will be the only German scientist to represent the renowned journal for the next three years. The appointment is tantamount to an award for his research on the influence of the ubiquitin system on tumour development.
"Oncogene has gained an excellent reputation in tumour research, and I am honoured to be part of this renowned journal as an Associated Editor," says the Würzburg scientist. The journal is one of the world’s leading publications for cancer research. It focuses on the cellular and molecular biology of cancer, resistance to cancer therapies and the development of new approaches to improve survival.
In his role as Associated Editor, Markus Diefenbacher acts as an ambassador for the journal. He evaluates manuscripts and nominates reviewers for evaluation according to the peer review principle. He also actively shapes the direction and focus of the journal.
"The selection of Markus Diefenbacher by Oncogene shows that he and the topic of his work are perceived internationally and assessed as relevant for oncological research. The nomination is a personal success for him, but also for the MSNZ programme of the German Cancer Aid, which is committed to promoting young scientists in oncology," says Dr. Martin Czolbe, scientific coordinator of the MSNZ.
Career of the scientistMarkus Diefenbacher, a native of the city of Karlsruhe in Germany, obtained his doctorate in genetics at the Karlsruhe Institute of Technology (KIT). He specialised in tumour research during his postdoctoral work at the Cancer Research UK London Research Institute (CRUK-LRI) and at The Francis Crick Institute London.
Since moving to Würzburg 2015, his research group has gained international renown for the development of new translational in vivo models as well as organoids that are used as preclinical test platforms for testing new therapeutics.